SG11201809229VA - Pharmaceutical composition - Google Patents
Pharmaceutical compositionInfo
- Publication number
- SG11201809229VA SG11201809229VA SG11201809229VA SG11201809229VA SG11201809229VA SG 11201809229V A SG11201809229V A SG 11201809229VA SG 11201809229V A SG11201809229V A SG 11201809229VA SG 11201809229V A SG11201809229V A SG 11201809229VA SG 11201809229V A SG11201809229V A SG 11201809229VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- ucb
- rule
- freeze
- pct
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 238000004108 freeze drying Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 1
- 229930006000 Sucrose Natural products 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000005720 sucrose Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 16 November 2017 (16.11.2017) WIPO I PCT omit IIl mum o oimIE (10) International Publication Number WO 2017/194646 Al (51) International Patent Classification: A61K 39/395 (2006.01) A61K 9/08 (2006.01) A61K 9/19 (2006.01) A61K 47/26 (2006.01) (21) International Application Number: PCT/EP2017/061261 (22) International Filing Date: 11 May 2017 (11.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1608323.0 12 May 2016 (12.05.2016) GB (71) Applicant: UCB BIOPHARMA SPRL [BE/BE]; 60, Al- lee de la Recherche, 1070 Brussels (BE). (72) Inventors: YATES, Andrew Jeffrey; c/o IPD, UCB Cell- tech, 208 Bath Road, Slough Berkshire SL1 2DT (GB). MASSANT, Jan Ivo; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). (74) Agent: UCB INTELLECTUAL PROPERTY; c/o UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: PHARMACEUTICAL COMPOSITION Fig. 1 70 (57) : The present invention relates to pharmaceutical compositions comprising an antibody or a fragment thereof suitable for freeze-drying (i.e. lyophilizing) The pharmaceutical compositions, which comprise an antibody or an antigen-binding fragment thereof; from 1 % to 20% w/v sucrose; an amino acid or a mixture of amino acids; and surfactant, are provided as pharmaceutical compositions for freeze-drying; as freeze-dried (i.e. lyophilized) compositions which can be reconstituted into a solvent at the time of use or as reconstituted liquid formulations ready for administration. [Continued on next page] WO 2017/194646 Al MIDEDIMOMOIDEIROIDEMOMOIROMINIfillOINVOIMIE TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(1i)) of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1608323.0A GB201608323D0 (en) | 2016-05-12 | 2016-05-12 | Pharmaceutical compositions |
| PCT/EP2017/061261 WO2017194646A1 (en) | 2016-05-12 | 2017-05-11 | Pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809229VA true SG11201809229VA (en) | 2018-11-29 |
Family
ID=56320265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809229VA SG11201809229VA (en) | 2016-05-12 | 2017-05-11 | Pharmaceutical composition |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11407835B2 (en) |
| EP (1) | EP3454899B1 (en) |
| JP (1) | JP7126454B2 (en) |
| KR (1) | KR102436694B1 (en) |
| CN (1) | CN109069643A (en) |
| AR (1) | AR108449A1 (en) |
| AU (1) | AU2017264553A1 (en) |
| BR (1) | BR112018072264A2 (en) |
| CA (1) | CA3022124A1 (en) |
| CL (1) | CL2018003178A1 (en) |
| CO (1) | CO2018011733A2 (en) |
| EA (1) | EA201892446A1 (en) |
| ES (1) | ES2977545T3 (en) |
| GB (1) | GB201608323D0 (en) |
| IL (1) | IL262654A (en) |
| MX (1) | MX2018013215A (en) |
| SG (1) | SG11201809229VA (en) |
| WO (1) | WO2017194646A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI703158B (en) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | Antibodies that specifically bind to tl1a |
| MA47106A (en) | 2016-12-21 | 2019-10-30 | Amgen Inc | ANTI-TNF ALPHA ANTIBODY FORMULATIONS |
| KR20250011715A (en) | 2017-03-11 | 2025-01-21 | 셀렉타 바이오사이언시즈, 인크. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| GB201708655D0 (en) * | 2017-05-31 | 2017-07-12 | Ucb Biopharma Sprl | Cell culture methods |
| MX2020009935A (en) * | 2018-03-23 | 2021-01-08 | Abbvie Deutschland | Stable aqueous anti-tau antibody formulations. |
| SG11202108627SA (en) | 2019-02-18 | 2021-09-29 | Lilly Co Eli | Therapeutic antibody formulation |
| BR112022018070A2 (en) * | 2020-03-11 | 2022-10-25 | Selecta Biosciences Inc | METHODS AND COMPOSITIONS RELATED TO SYNTHETIC NANOVEHICLES |
| EP4173637A4 (en) * | 2020-06-29 | 2024-08-07 | Hanall Biopharma Co., Ltd. | Formulation for anti-fcrn antibody |
| CN117615788A (en) * | 2021-05-12 | 2024-02-27 | 安奈普泰斯生物有限公司 | Antibody compositions |
| WO2023099607A1 (en) | 2021-12-01 | 2023-06-08 | UCB Biopharma SRL | Formulations comprising fab-peg |
| JPWO2023224112A1 (en) * | 2022-05-20 | 2023-11-23 | ||
| AU2023281650A1 (en) | 2022-05-30 | 2024-10-17 | Hanall Biopharma Co., Ltd. | Anti-fcrn antibody or antigen binding fragment thereof with improved stability |
| WO2024184444A1 (en) * | 2023-03-08 | 2024-09-12 | Immunovant Sciences Gmbh | High concentration protein formulations with polysorbate excipients and methods of making the same |
| WO2025056011A1 (en) * | 2023-09-13 | 2025-03-20 | 正大天晴药业集团股份有限公司 | Pharmaceutical composition comprising anti-pd-1 antibody and second antibody |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE454137T1 (en) * | 2001-07-25 | 2010-01-15 | Facet Biotech Corp | STABLE LYOPHILIZED PHARMACEUTICAL FORMULATION OF THE IGG ANTIBODY DACLIZUMAB |
| EP1697415A1 (en) * | 2003-11-12 | 2006-09-06 | Biogen Idec MA Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| CN101124245A (en) * | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
| US9283260B2 (en) | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
| WO2007132480A2 (en) * | 2006-05-12 | 2007-11-22 | Bharat Biotech International Limited | A composition useful as a vaccine |
| AR070315A1 (en) * | 2008-02-07 | 2010-03-31 | Merck & Co Inc | ANTIBODIES 1B20 ANTAGONISTS OF PCSK9 |
| AR070316A1 (en) * | 2008-02-07 | 2010-03-31 | Merck & Co Inc | PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN) |
| AU2010263058A1 (en) * | 2009-06-18 | 2012-01-12 | Wyeth Llc | Lyophilized formulations for small modular immunopharmaceuticals |
| US9072668B2 (en) | 2010-03-09 | 2015-07-07 | Janssen Biotech, Inc. | Non-aqueous high concentration reduced viscosity suspension formulations of antibodies |
| US8788028B2 (en) | 2010-07-28 | 2014-07-22 | Medtronic, Inc. | Parasympathetic stimulation to enhance tachyarrhythmia detection |
| US9458240B2 (en) | 2010-12-10 | 2016-10-04 | Novartis Pharma Ag | Anti-BAFFR antibody formulations |
| CA2830806C (en) | 2011-03-31 | 2020-05-12 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments |
| JOP20200043A1 (en) * | 2011-05-10 | 2017-06-16 | Amgen Inc | Ways to treat or prevent cholesterol disorders |
| US9592289B2 (en) * | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| PL2830658T3 (en) * | 2012-03-26 | 2019-02-28 | Sanofi | Stable igg4 binding agent formulations |
| GB201208370D0 (en) * | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
| WO2014093206A1 (en) | 2012-12-13 | 2014-06-19 | Merck Sharp & Dohme Corp. | Lyophilized spherical pellets of anti-il-23 antibodies |
| WO2015121318A1 (en) * | 2014-02-12 | 2015-08-20 | Sanofi | Anti-il-4/anti-il-13 bispecific antibody/polyglutamate formulations |
| RU2017111228A (en) | 2014-10-18 | 2018-11-21 | Пфайзер Инк. | Anti-IL-7R Antibody Compositions |
| GB201508180D0 (en) | 2015-05-13 | 2015-06-24 | Ucb Biopharma Sprl | Antibodies |
-
2016
- 2016-05-12 GB GBGB1608323.0A patent/GB201608323D0/en not_active Ceased
-
2017
- 2017-05-11 WO PCT/EP2017/061261 patent/WO2017194646A1/en not_active Ceased
- 2017-05-11 AU AU2017264553A patent/AU2017264553A1/en not_active Abandoned
- 2017-05-11 JP JP2018559221A patent/JP7126454B2/en active Active
- 2017-05-11 EP EP17725544.5A patent/EP3454899B1/en active Active
- 2017-05-11 US US16/300,522 patent/US11407835B2/en active Active
- 2017-05-11 SG SG11201809229VA patent/SG11201809229VA/en unknown
- 2017-05-11 CN CN201780028404.3A patent/CN109069643A/en active Pending
- 2017-05-11 KR KR1020187036132A patent/KR102436694B1/en active Active
- 2017-05-11 CA CA3022124A patent/CA3022124A1/en active Pending
- 2017-05-11 AR ARP170101248A patent/AR108449A1/en not_active Application Discontinuation
- 2017-05-11 MX MX2018013215A patent/MX2018013215A/en unknown
- 2017-05-11 EA EA201892446A patent/EA201892446A1/en unknown
- 2017-05-11 BR BR112018072264-2A patent/BR112018072264A2/en not_active IP Right Cessation
- 2017-05-11 ES ES17725544T patent/ES2977545T3/en active Active
-
2018
- 2018-10-28 IL IL262654A patent/IL262654A/en unknown
- 2018-10-30 CO CONC2018/0011733A patent/CO2018011733A2/en unknown
- 2018-11-08 CL CL2018003178A patent/CL2018003178A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB201608323D0 (en) | 2016-06-29 |
| AU2017264553A1 (en) | 2018-12-13 |
| BR112018072264A2 (en) | 2019-02-12 |
| CO2018011733A2 (en) | 2019-02-08 |
| EP3454899B1 (en) | 2024-03-20 |
| MX2018013215A (en) | 2019-02-21 |
| JP2019514998A (en) | 2019-06-06 |
| KR20190008320A (en) | 2019-01-23 |
| EP3454899A1 (en) | 2019-03-20 |
| CN109069643A (en) | 2018-12-21 |
| CL2018003178A1 (en) | 2019-02-01 |
| CA3022124A1 (en) | 2017-11-16 |
| AR108449A1 (en) | 2018-08-22 |
| US11407835B2 (en) | 2022-08-09 |
| RU2018141591A (en) | 2020-06-15 |
| JP7126454B2 (en) | 2022-08-26 |
| WO2017194646A1 (en) | 2017-11-16 |
| EA201892446A1 (en) | 2019-04-30 |
| ES2977545T3 (en) | 2024-08-26 |
| KR102436694B1 (en) | 2022-08-25 |
| EP3454899C0 (en) | 2024-03-20 |
| RU2018141591A3 (en) | 2021-01-13 |
| IL262654A (en) | 2018-12-31 |
| US20200048346A1 (en) | 2020-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809229VA (en) | Pharmaceutical composition | |
| SG11201908540PA (en) | Stable antibody formulation | |
| SG11201909646TA (en) | Trem2 antigen binding proteins and uses thereof | |
| SG11201810327XA (en) | Single domain serum albumin binding protein | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201810023QA (en) | Anti-tim-3 antibodies and methods of use thereof | |
| SG11201808799SA (en) | Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors | |
| SG11201808242UA (en) | Methods for inhibiting angiogenesis in a subject in need thereof | |
| SG11201901444PA (en) | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
| SG11201900745VA (en) | Substituted thiazolo-pyridine compounds as malt1 inhibitors | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201811363YA (en) | Anti-zika virus antibodies and methods of use | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201408174UA (en) | Antibody formulation | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201807597UA (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| SG11201808710UA (en) | Novel immunogenic cd1d binding peptides |